Hepatobiliary Department, Beijing 302 Hospital, Beijing 100039, P.R. China.
Department of Cardiology, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China.
Mol Med Rep. 2019 Mar;19(3):1587-1594. doi: 10.3892/mmr.2019.9832. Epub 2019 Jan 8.
The SET domain‑containing 1B (SETD1B) gene is involved in multiple biological processes, including tumor development and progression. However, the role of SETD1B in hepatocellular carcinoma (HCC) is largely unexplored. The present study, examined the expression of SETD1B in patients with HCC and assessed its clinical significance. Reverse transcriptase quantitative polymerase chain reaction and western blot analysis results revealed that the expression levels of SETD1B mRNA and protein were significantly increased in HCC tumor tissues compared with the adjacent normal tissues. In addition, an analysis of the patient clinical factors indicated that increased levels of SETD1B expression were associated with tumor size, clinical stage and liver cirrhosis. Patients with HCC with decreased levels of SETD1B expression exhibited longer survival times compared with those with increased levels of SETD1B expression. In addition, Cox's regression analysis results implied that the upregulation of SETD1B was an independent prognostic marker in patients with HCC. Taken together, the results demonstrated that SETD1B is essential in the progression of HCC and may be used as a potential prognostic marker and therapeutic target in HCC.
SET 结构域包含蛋白 1B（SETD1B）基因参与多种生物学过程，包括肿瘤的发生和发展。然而，SETD1B 在肝细胞癌（HCC）中的作用在很大程度上尚未被探索。本研究检测了 HCC 患者中 SETD1B 的表达，并评估了其临床意义。逆转录定量聚合酶链反应和 Western blot 分析结果显示，SETD1B mRNA 和蛋白的表达水平在 HCC 肿瘤组织中明显高于相邻正常组织。此外，对患者临床因素的分析表明，SETD1B 表达水平的升高与肿瘤大小、临床分期和肝硬化有关。SETD1B 表达降低的 HCC 患者的生存时间明显长于 SETD1B 表达升高的患者。此外，Cox 回归分析结果表明，SETD1B 的上调是 HCC 患者的独立预后标志物。综上所述，这些结果表明 SETD1B 在 HCC 的进展中是必不可少的，可能成为 HCC 的潜在预后标志物和治疗靶点。
